Metabolic medicines and addiction: what GLP-1 receptor agonists might add to substance use care

BMJ 2026 Open access

Read full text

Authors: Fares Qeadan

DOI: 10.1136/bmj.s325

Cited by: 5

References: 11

Abstract

Clinical trials and equitable care pathways are needed to build on early evidence of benefit

Diabetes Treatment and Management Pharmacology and Obesity Treatment Diabetes Cardiovascular Risks and Lipoproteins

References 11